Skip to content

Homeopathy for Major Depressive Disorder

Homeopathy for Major Depressive Disorder: protocol for N-of-1 studies - HOMDD-1

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000050075
Enrollment
10
Registered
2023-01-18
Start date
2023-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Interventions

Homeopathy: Individualized homeopathic medication following the method of the sixth edition of the Organon Placebo: Indistinguishable solution containing 20 ml of 30% alcohol, administered in the sam

Sponsors

Federal University of Ceara. Hospital Universitario Walter Cantidio
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Women and men at age over 18 years, with a diagnosis of a Major Depressive Episode given by a psychiatrist, according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V), presenting a therapeutic response (reduction greater than or equal to 50 percent of the baseline depression score, kept for at least four weeks) during a prior open homeopathic treatment, with or without concomitant use of psychotropic drugs. The capacity to understand and agree and a written consent form with the terms and procedures of the study will be necessary for inclusion.

Exclusion criteria

Exclusion criteria: Suicidal behavior (defined as attempted suicide within 24 months) and psychotic symptoms.

Design outcomes

Primary

MeasureTime frame
Score of the Beck-II Depression Inventory (BDI-II), self-evaluated by the participant in weeks 0-2-4-8-12-16-20-24-28 and analyzed throughout the study in homeopathy and placebo partitions.

Secondary

MeasureTime frame
Evaluated in weeks 0-2-4-8-12-16-20-24-28: score of the Clinical Global Impression Scale; mental and physical health scores assessed by the 12-Item Short-Form Health Survey (SF-12); participant's blinded preference for verum or placebo treatment at each block; clinically substantial worsening (characterized by an augmentation in BDI inclusion score greater than or equal to 30%), and Adverse Events.

Countries

South America

Contacts

Public ContactLia Sanders

Federal University of Ceara Department of Medicine

lia_sanders@hotmail.com00558533668004

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026